Technical Analysis for RXDX - Prometheus Biosciences, Inc.

Grade Last Price % Change Price Change
C 25.99 5.87% 1.44
RXDX closed up 5.87 percent on Friday, April 16, 2021, on 40 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical RXDX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength 5.87%
Wide Bands Range Expansion 5.87%
Overbought Stochastic Strength 5.87%
Older End-of-Day Signals for RXDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Prometheus Biosciences, Inc. Description

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Immunology Inflammatory Bowel Disease Tumor Necrosis Factor Inflammatory Bowel Diseases

Is RXDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.33
52 Week Low 16.11
Average Volume 213,987
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 20.67
10-Day Moving Average 21.60
Average True Range 2.63
ADX 0.0
+DI 24.98
-DI 21.32
Chandelier Exit (Long, 3 ATRs ) 20.43
Chandelier Exit (Short, 3 ATRs ) 24.01
Upper Bollinger Band 25.74
Lower Bollinger Band 15.59
Percent B (%b) 1.02
BandWidth 49.14
MACD Line 1.06
MACD Signal Line 0.29
MACD Histogram 0.7701
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.81
Resistance 3 (R3) 30.35 28.30 30.00
Resistance 2 (R2) 28.30 27.07 28.52 29.73
Resistance 1 (R1) 27.14 26.31 27.72 27.60 29.47
Pivot Point 25.09 25.09 25.38 25.31 25.09
Support 1 (S1) 23.93 23.86 24.51 24.39 22.51
Support 2 (S2) 21.88 23.10 22.10 22.25
Support 3 (S3) 20.72 21.88 21.98
Support 4 (S4) 21.18